StockData
Amgen Inc logo

Amgen Inc (AMGN) operating KPIs

AMGNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026Score 17/3039% above fair value
$466.01+5.28 (+1.15%)

Close on Oct 30, 2026Market cap $251.94BP/E 28.9Yield 2.07%

Amgen eVENITY (romosozumab-aqqg — Postmenopausal Osteoporosis) — Worldwide product sales ($M) ($M)

Form 10-Q / 10-K Segment & Revenue Disaggregation Note & Form 8-K Product Sales Detail

Latest, FY2025
2,100
Period ended Dec 31, 2025
Change on a year earlier
+34.4%
1,563 in FY2024
History
7 years
Since FY2019
Sources
5
Documents cited below

Annual history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedEVENITY (romosozumab-aqqg — Postmenopausal Osteoporosis) — Worldwide product sales ($M) ($M)Year on yearSource
FY2025Dec 31, 20252,100+34.4%Form 10-K (filed 2026-02-13) ↗
FY2024Dec 31, 20241,563+34.7%Form 10-K (filed 2026-02-13) ↗
FY2023Dec 31, 20231,160+47.4%Form 10-K (filed 2026-02-13) ↗
FY2022Dec 31, 2022787+48.5%Form 10-K (filed 2025-02-14) ↗
FY2021Dec 31, 2021530+51.4%Form 10-K (filed 2024-02-14) ↗
FY2020Dec 31, 2020350+85.2%Form 10-K (filed 2023-02-09) ↗
FY2019Dec 31, 2019189–Form 8-K (amgn-20191231xq4ex991.htm, filed 2020-01-30) ↗

Breakdown

What makes up evenity (romosozumab-aqqg — postmenopausal osteoporosis) — worldwide product sales ($m)

Cite this data

StockData. (2026). Amgen EVENITY (romosozumab-aqqg — Postmenopausal Osteoporosis) — Worldwide product sales ($M) ($M), annual FY2019–FY2025 [Data set]. Compiled from Amgen SEC filings and investor materials. https://stockdatahq.com/stocks/amgn/kpis/prod_evenity_ww

See every metric in the Amgen KPI table. Data updated Oct 28, 2026.